Kennedy R. Lees
University of Glasgow
467 Papers
3.9K Citations
Kennedy R. Lees is an academic researcher from University of Glasgow. The author has contributed to research in topics: Stroke & Medicine. The author has an hindex of 86, co-authored 455 publications. Previous affiliations of Kennedy R. Lees include Ludwig Maximilian University of Munich & Cedars-Sinai Medical Center.
Chat about Author
Papers
How a Sequential Design Would Have Affected the GAIN International Study of Gavestinel in Stroke
TL;DR: Four sequential reconstructions of the GAIN study made under various scenarios show that sequential designs appear to be an attractive option for trials in stroke.
6
Xanthine oxidase inhibition and white matter hyperintensity progression following ischaemic stroke and transient ischaemic attack (XILO-FIST): a multicentre, double-blinded, randomised, placebo-controlled trial
Jesse Dawson,Michele Robertson,David Alexander Dickie,P. Bath,Kirsten P. Forbes,Terence Quinn,Niall M. Broomfield,Krishna A Dani,A. Doney,J. Graeme Houston,Kennedy R. Lees,A. W. Muir,Allan D. Struthers,Matthew Walters,Mark Barber,Ajay Bhalla,Alan Cameron,Alexander G. Dyker,Paul Guyler,A Hassan,Mark T. Kearney,Breffni C Keegan,Sekaran Lakshmanan,Mary Joan MacLeod,Marc Randall,Louise Shaw,Ganesh Subramanian,David J. Werring,Alex McConnachie +28 more
TL;DR: In this paper , a multicentre, prospective, randomised, double-blinded, placebo-controlled trial conducted in 22 stroke units in the United Kingdom, randomly assigned participants within 30-days of ischaemic stroke or TIA to receive oral allopurinol 300 mg twice daily or placebo for 104 weeks.
6
Pharmacodynamic, pharmacokinetic and humoral effects of oral zabicipril, an angiotensin converting enzyme inhibitor in normotensive man.
TL;DR: These initial studies suggest that zabicipril is a well tolerated inhibitor of converting enzyme with near maximal inhibitory effect occurring at a dose of 2.5 mg, and the dose range after single and multiple doses is indicated.
6